Integra pre-announces Q4 rev ~$397-398M, adj EPS above guidance; FY rev ~$1,557-1,558M

INTEGRA LIFESCIENCES HOLDINGS CORP

2022-FY EPS reported $2.16 revenue$1,557,666,000

Q4 2022 revenue expected $397M-$398M, down ~2% reported, up ~3% organic vs Q4 2021.
Adjusted EPS expected above high end of October guidance range.
FY2022 revenue expected $1,557M-$1,558M, up ~1% reported, +4% organic.
Full-year adjusted EPS above high end of October guidance and above midpoint of original Feb guidance.
Company presenting at JP Morgan Healthcare Conference on Jan 11, 2023.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

INTEGRA LIFESCIENCES HOLDINGS CORP updated its fourth quarter and full-year 2022 guidance (reaffirmed).

Period: fourth quarter and full-year 2022
Guidance: reaffirmed
Result: preliminary results

Exact text from the filing

On January 10, 2023, Integra LifeSciences Holdings Corporation (the "Company") issued a press release announcing certain unaudited, preliminary fourth quarter and full-year 2022 financial results.

View on SEC.gov

13 earnings releases filed in the last 30 days. Browse all earnings releases →

INTEGRA LIFESCIENCES HOLDINGS CORP filing history →

Source: SEC EDGAR

accession 0000917520-23-000003

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.